Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
Older
Nov 15, 2024
Investor presentation, 15 November 2024
Nov 14, 2024
Notification of buy-back - NEU
Nov 14, 2024
Neuren announces A$50m on-market share buy-back program
Nov 07, 2024
Q3 2024 update
Nov 07, 2024
Pause in Trading
Nov 06, 2024
PRV sold for US$150m - Neuren to receive one third
Nov 01, 2024
Updated Share Trading Policy
Oct 28, 2024
Notification of cessation of securities - NEU
Oct 17, 2024
DAYBUE receives marketing authorization in Canada
Oct 07, 2024
NEU continues PMS P3 preparations after positive FDA meeting
1
2
3
4
5
6
Next
